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Abstract: The development of antiretroviral (ARV)-based prevention products has the potential to 
substantially change the HIV prevention landscape, yet little is known about how appealing these 
products will be - compared to existing options - outside of clinical trials. We conducted a discrete 
choice experiment (DCE) to measure preferences for five new products among four important 
populations in the HIV response: adult men and women in the general population (aged 18-49), 
adolescent girls (aged 16-17), and self-identifying female sex workers (aged 18-49). We interviewed 
661 self-reported HIV negative participants in peri-urban South Africa, who were asked to choose 
between three unique, hypothetical products over ten choice sets. Data were analysed using 
multinomial, latent class and mixed multinomial logit models. HIV protection was the most important 
attribute to respondents; however, results indicate significant demand among all groups for 
multipurpose prevention products which offer protection from HIV infection, other STIs, and 
unwanted pregnancy. All groups demonstrated a strong preference for long-lasting injectable 
products. There was substantial heterogeneity in preferences within and across population groups. 
These results suggest that stimulating demand for new HIV prevention products may require a more 
a nuanced approach than simply developing highly effective products. No one product is likely to be 
equally attractive or acceptable across different groups. This study strengthens the call for effective 
and attractive multipurpose prevention products to be deployed as part of a comprehensive 
combination prevention strategy. 
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Introduction  
South Africa has the largest HIV epidemic in the world, but the health and economic burden of HIV 
infection is not borne equally.1 Women are 40% more likely to be living with HIV than men, whilst 
adolescent girls (aged 15-19 years) face an 80% cumulative lifetime risk of HIV acquisition.2, 3 Female 
sex workers (FSW) are designated as a key population for HIV treatment and prevention and estimates 
suggest that the HIV prevalence among this group in Johannesburg is 72%.4  
Recent technological developments have led to a number of candidate products for antiretroviral 
(ARV)-based HIV prevention.5 Yet before these are introduced, it is important to understand who will 
use them to reliably estimate their impact and best plan their introduction. Where different 
population groups have different preferences for products it is critical that this heterogeneity is 
identified to ensure that relevant products are made available to potential users. Even if only a small 
proportion of the population only uses products, they may still be cost-effective if used consistently 
and effectively among those at risk of HIV acquisition. ARV-based pre-exposure prophylaxis (PrEP) has 
been shown to offer varying degrees of protection to HIV negative persons when delivered via daily 
or intermittent oral tablet6, 7 or long-lasting intravaginal ring8, 9. However, product protection has been 
variable during clinical trials as microbicide gels and vaginal rings were found to confer substantially 
less protection to younger users than to older women primarily due to adherence issues.8, 10 This is 
particularly concerning as adolescent girls and young women (AGYW) face a far greater risk of HIV 
acquisition than older women, or men of any age.3, 10  
A promising field in HIV prevention is the development of multipurpose technologies (MPTs), products 
which simultaneously provide protection from two or more of HIV, other STIs, and unintended 
pregnancy.11, 12 Current MPTs in development include: (1) long-acting drug delivery systems such as 
intravaginal rings designed to protect from HIV infection and pregnancy (currently in a phase-I trial, 
ClinicalTrials.gov Identifier: NCT02235662); (2) pericoital drug delivery systems such as vaginal gel, 
tablets and films designed to protect from HIV; and (3) a combination of products such as a 
contraceptive diaphragm used with microbicide gel designed to protect from HIV, STIs and 
pregnancy.11, 13 Although MPT development is likely to be costly and complex, their benefits may also 
be large. Firstly, products offering more than one indication may be more attractive to potential users 
than single purpose products. Secondly, MPT use could crowd-in protection from lesser valued 
attributes. For example, where users value contraceptive properties more than they do HIV 
prevention, additional HIV protection would be a positive externality from the use of a dual-protective 
product. Thirdly, the multipurpose nature of MPTs may reduce the stigma of accessing HIV prevention 
tools, which has been shown to be a substantive barrier to use, and prevent products from being 
perceived as for certain populations only.14, 15 
Accounting for the perspectives of end-users in product formulation and delivery could lead to more 
attractive products, greater uptake and adherence, and increased population protection. This study 
uses a discrete choice experiment (DCE) to elicit the preferences for five HIV prevention products (oral 
PrEP, a microbicide gel, a SILCS diaphragm used in concert with gel, an intravaginal ring, and an 
injectable) from four population groups (adult men and women aged 18-49, adolescent girls aged 16-
17 and self-identifying female sex workers aged 18-49) in Vosloorus, a township in peri-urban 
Ekurhuleni, around 30km from Johannesburg in the Gauteng province of South Africa. Because there 
are no observed data for many of these products, we gathered primary stated preference data using 
the DCE, an end-user focused approach to identifying key determinants of demand.16, 17 DCEs ask 
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respondents to choose their preferred product or service from a set of alternatives over a number 
(usually between 8-10) of choice tasks. By looking at how respondents choose across repeated 
scenarios allows researchers to quantitatively elicit the key drivers of decision making.18 Although men 
who have sex with men (MSM) are a high-risk group in South Africa, they were not purposively 
sampled in this study a) because the contraceptive indication of interest would have little relevance 
among MSM practicing solely same-sex intercourse, b) the stigma associated with same-sex activity 
was considered to place interviewers or participants at risk, and c) the small number of MSM likely to 
be in the geographical location of the survey coupled with the intensive resources required to reach 
adolescent and FSW groups. Where a small number of MSM were identified the household survey, 
they were not excluded from data collection or analysis based on reported same-sex activity. 
Already popular in the health literature19, DCEs are being increasingly applied in the HIV and sexual 
health fields. Previous work conducted in South Africa found HIV prevention efficacy to be a key driver 
of demand for a microbicide, a diaphragm or female condom.20 A DCE was used to indicate that a 
rectal microbicide was acceptable among MSM in Thailand, with male sex workers more likely to use 
an efficacious product than other men.21 A DCE in Tanzania showed that different population groups 
had markedly different preferences for HIV testing interventions among respondents who had been 
tested previously.22 Two DCEs in Malawi found heterogeneity in the preferences of young people for 
HIV, sexual health, and family planning services.23, 24 Finally, a conjoint analysis in seven countries 
found PrEP to be broadly acceptable to potential end-users.25 
To our knowledge, this is the first study to explore how preferences for new HIV prevention products 
vary across general and key population groups, and provides important information on a) preferences 
among different groups, b) variation in preferences within groups, and c) whether new products will 
be used alongside or instead of condoms. Such “condom migration” has been a concern in the design 
of PrEP programmes and demonstration projects, yet evidence is mixed as to whether condomless sex 
will increase after PrEP introduction.6, 26-28 
Methods 
Study context 
Primary data collection was carried out in the town of Vosloorus, around 30km south-east of 
Johannesburg, South Africa. Vosloorus contains a broad range of residential contexts representing a 
range of demographic, socioeconomic and cultural characteristics. Formative research took place 
between August and September 2015, and the survey ran from October to December 2015. Further 
details on study context and methods have been published in the study protocol29 and no changes 
were made to the study design or analysis plan.  
Development and design of the discrete choice experiment 
The DCE was developed through an analysis of a previous DCE and focus groups discussions carried 
out in previous research18, 21, specifically identifying important characteristics of prevention products 
and exploring optimal ways to present these in a clear and relatable manner to participants. This was 
supplemented by a scoping literature review to identify new products and additional attributes which 
could be important to respondents, which was added to and refined through piloting. We opted to 
show three alternatives of new products in each task using an unlabelled design where each 
alternatives represent a generic product within which all characteristics can change as prescribed by 
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the statistical design. Though an unlabelled design, were each alternative represents a fixed product 
category, would have led to greater statistical efficiency, feedback from piloting was that a choice task 
with five labelled alternatives plus an opt-out was too complex. The opt-out alternative displayed 
characteristics of a male condom or non-protection, depending on what the respondent reported 
using in their last sex act.  
The DCE was pre-piloted among 17 respondents from across the target populations. A separate design 
was generated for male and female groups as men can only initiate use of two of the five potential 
products (the injectable and oral PrEP). The full survey and DCE was then piloted among 45 
respondents from the target sampling frame. Few changes were made to the DCE after piloting, except 
to the side-effects attribute where minor and frequent side-effect symptoms of nausea, stomach 
cramps, and dizziness were included over major, less frequent side-effects such as reduction in bone 
mineral density or liver toxicity. This is a limitation of this study, but was necessary due to difficulties 
in participant comprehension of a) varying probabilities of side-effects and b) medical implications of 
more serious conditions in a brief DCE interview. Priors from analysis of pilot data (n=17) were used 
in NGENE software30 to generate a single D-efficient design with ten tasks, which avoided dominated 
or duplicated alternatives as recommended31. A D-efficient design was chosen with the aim of 
improving precision in final model estimates whilst accounting for design constraints arising from 
restrictions on the frequency that products could be used. The final six attributes of the DCE and their 
levels are shown in Table 1, and Figure 1 shows an example of how choice tasks were presented to 
respondents who reported using a condom in their last sex-act. For participants who reported not 
using a condom at last sex, the final column showed a “nothing” alternative, whilst male respondents 
saw identical side-effects images but with male characters. The final design incorporated ten choice 
tasks, with one additional task a repeat to check the consistency of responses. 
<Table 1 here> 
<Figure 1 here> 
Survey methods 
A household survey sampled adult men and women (aged 18-49), and adolescent girls (aged 16-17) 
randomly. Clusters of dwellings (census enumeration areas) within Ekurhuleni were selected at 
random using municipal data and aerial photographs, and interviewers contacted every second 
property after a random start. All eligible participants were interviewed within selected households. 
The DCE and background survey was administered in English, Zulu and Khosa languages using Open 
Data Kit (https://opendatakit.org) software on tablet computers, and participants were given ZAR 50 
(GBP £2.50) vouchers as compensation for their time. A team of twelve experienced interviewers from 
a specialist local data collection firm, Progressus Research and Development 
(http://www.progressus.co.za) implemented the survey.  
FSWs are a hard to reach population and we used respondent-driven sampling (RDS) to sample 203 
active FSW participants.32 Peer educators, most of whom were practicing sex workers, were used to 
locate ‘hotspots’ in Ekurhuleni. First, 12 were asked to act as ‘seeds’ to start RDS chains in different 
areas (i.e. women working in brothels, hotels or on the street). Seeds were invited to complete the 
survey and received the same ZAR 50 (GBP £2.50) compensation as participants in the general 
population. Women were then given four coupons containing study information to distribute to 
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colleagues. When each referred colleague attended for interview, their recruiter received a small 
incentive in the form of a ZAR 20 (GBP £1) voucher. 
Choice Modelling 
We model choices using random utility models, choosing this approach over alternative methods 
(random regret minimisation for example) due to its proven consistency in explaining choice 
behaviour in health applications. We assume that that individual i(i=1,…,N) makes choices such that 
they maximise utility over the four alternatives presented (j=1,2,3,4). Their axiomatic utility function 
Uij is decomposed into an explainable systematic component Vij and a random component εij, and we 
specify an indirect utility function for the utility of respondent i from choice j in choice set c as the 
linear combination of attributes and an error term: 
𝑉𝑖𝑗𝑐 = 𝑋𝑖𝑗𝑐𝛽 + 𝜀𝑖𝑗𝑐 (1) 
With 𝑉𝑖𝑗𝑐 the utility derived from a choice, 𝑋𝑖𝑗𝑐
′ 𝛽 the component of utility that is captured by DCE 
attributes, and 𝜀𝑖𝑗𝑐 a stochastic (random) component of utility. We specify the vector 𝑋𝑖𝑗𝑐  as the set 
of product attributes: 
𝑋𝑖𝑗𝑐𝛽𝑗 = 𝛽0 +  𝛽1𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑗 + 𝛽2𝐻𝐼𝑉𝑗 + 𝛽3𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑒𝑝𝑡𝑖𝑜𝑛𝑗 + 𝛽4𝑆𝑇𝐼𝑗 + 𝛽5𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑗
+ 𝛽6𝑆𝑖𝑑𝑒𝐸𝑓𝑓𝑒𝑐𝑡𝑠𝑗 
(2) 
 
Where 𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑗, 𝐻𝐼𝑉𝑗, 𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑒𝑝𝑡𝑖𝑜𝑛𝑗, 𝑆𝑇𝐼𝑗, 𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑗, and 𝑆𝑖𝑑𝑒𝐸𝑓𝑓𝑒𝑐𝑡𝑠𝑗 are the design 
attributes of the DCE, and 𝛽0 a constant. We first estimate equation (1) using a multinomial (or 
conditional) logit model (MNL) which estimates the probability of individual i choosing alternative j 
among the set of options c as a probabilistic function of design attributes: 
𝑃𝑖𝑗𝑐 =
exp (𝑋𝑖𝑗𝑐𝛽)
∑ exp (𝐽 𝑋𝑖𝑗𝑐𝛽)
 
(3) 
Although described as the workhorse of discrete choice modelling, the MNL requires two restrictive 
assumptions: the IIA assumption of independence of irrelevant alternatives (concordant with the IID 
distribution of the disturbance), and homogenous preferences across individuals where every 
individual is assumed to have the same tastes as the sample average, which does not allow us to 
uncover differences in preferences that are important in guiding policy.18 We assume that individuals 
choose the service associated with the highest utility such that the probability that individual i chooses 
alternative j over k is given as: 
Pr 𝑗𝑖 = Pr(𝑈𝑗𝑖 > 𝑈𝑘𝑖) = Pr(𝑉𝑗𝑖 + 𝜀𝑗𝑖 >  𝑉𝑘𝑖 + 𝜀𝑘𝑖) = Pr(𝑉𝑗𝑖 − 𝑉𝑘𝑖 > 𝜀𝑗𝑖 − 𝜀𝑘𝑖) (4) 
In this paper, as different MNL models are estimated for each population, the assumption required is 
homogeneity of preferences within each group. As groups are more homogenous in nature due to 
separate inclusion criteria, assuming identical preferences across members within each group may be 
less restrictive than assuming this across the range of populations in our sample.  
Nevertheless, to recognise that individuals within groups may have different preferences, we apply a 
random parameter logit (MMNL or mixed logit random parameter) model. The MMNL allows for 
7 
 
preference (taste) heterogeneity within groups so does not require the IIA assumption to hold. Briefly, 
the MMNL extends the MNL model by decomposing the error term into two components: 
𝑈𝑖𝑗 = 𝑉𝑖𝑗 + [𝛤𝑖𝑗 + 𝜀𝑖𝑗] (5) 
Which, when the distribution of the random component 𝛤𝑖𝑗  is specified by the analyst, is used to 
estimate individual-level coefficients: 
𝛽𝑖𝑘 = 𝛽𝑘 + 𝛿𝑘𝑍𝑖 + 𝛤𝑘𝑣𝑖𝑘 (6) 
Where 𝛿𝑘𝑍 reflects observable heterogeneity, and 𝛤𝑘𝑣𝑖𝑘 unobservable heterogeneity.  
Finally, we use a latent class approach to explore unobserved heterogeneity in choice data. A semi-
parametric approach, a latent class model assumes the existence of underlying subgroups (classes) of 
respondents whose membership of each class is characterised by unobserved, or latent, variables. A 
posterior probability is assigned to each participant for membership to each class, and when 
participants are allocated to classes based on their highest probability it is possible to compare the 
observable characteristics of participants across classes 18, 34. 
Latent class modelling offers a different approach to relaxing the IIA assumption of the MNL model. 
Furthermore the basic latent class model does not require parametric distributional assumptions to 
be imposed by the analyst, whilst results have been shown less sensitive to computational variations 
in estimation, such as starting values or optimisation algorithms which can vary across software 
packages.35, 36 A latent class approach estimates separate parameter vectors for different classes of 
the sample with MNL models. The model relaxes the IIA assumption by assuming that preferences are 
homogenous within, but not across, classes. Thus the probability of respondent i choosing alternative 
j in choice set c conditional on class membership k is: 
𝑃𝑖𝑐(𝐽|𝛽𝑘) =  ∑ 𝜋𝑖𝑘
𝐾
𝑘=1
exp (𝑋𝑖𝑗𝑐𝛽𝑘)
∑ exp (𝐽 𝑋𝑖𝑗𝑐𝛽𝑘)
 
(7) 
The probability of respondent i belonging to class k is 𝜋𝑖𝑘. Class membership is unobservable, 
however, we can regress the probability of class membership on a set of observable characteristics 
such that: 
𝜋𝑖𝑘 =
exp (𝑍𝑖
′𝛿𝑘)
∑ exp (𝑍𝑖
′𝛿𝑘)
𝐾
𝑘=1
 
(8) 
With Zi a vector of individual characteristics, and 𝛿𝑘  a vector of parameters to be estimated. 
We run latent class logit models on the male sample, alongside a pooled sample of all three female 
groups. This approach removes the implicit assumption that women’s preferences will differ by their 
sample category, and instead allows the data to drive evidence of variation and similarity among 
subgroups. By pooling we lose generalisability from the results of this specification; however, results 
from the pooled analysis are useful to identify important subgroups of the female population.  We 
assess the optimal number of classes through comparison of model fit via log-likelihood function and 
Akaike Information Criteria (AIC). 
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Heterogeneity 
We use two approaches to explore heterogeneity in preferences. First, we examine the distribution 
parameters of the MMNL model to see where variation remains in addition to that captured by the 
random parameters. Secondly, we estimate the latent class model (equation 8) and explore how 
preferences vary by class, specifying several observable characteristics (Error! Reference source not 
found.) which influence the probability of class membership.  
Our rationale for including these observable characteristics is as follows. Age is strongly associated 
with HIV and pregnancy risk37, 38, yet little is known about the effect of age on preferences for 
protection against HIV or pregnancy. Structural drivers are legal, economic and social factors which 
shape HIV risk.39 Exposure to intimate partner violence (IPV) has been shown to be associated with 
increased HIV risk in many contexts40, 41, whilst limited livelihood opportunities, and unrestricted 
alcohol availability alongside drinking norms are also significant factors in HIV risk.42-45 Finally, life 
circumstances play an important role in the extent to which people place themselves at, or are able 
to protect themselves from, HIV risk.46, 47 We therefore explore attitudes towards pregnancy among 
women and how preferences may be affected by male circumcision, which reduces the likelihood of 
a male acquiring HIV.48, 49 Finally, we explore associations with protective attributes, having an external 
partner in the previous three months, and having high HIV knowledge as assessed by the number of 
correct answers on a knowledge tool.50  
Model estimation 
Models were estimated in NLOGIT 551 through a maximum likelihood approach and MMNL models 
were estimated using 500 Halton draws with start values obtained from a MNL model. All parameters 
were generic across three unlabelled alternatives, with labels entering the DCE through an attribute 
level. All design attributes were specified as random with parameters following a normal distribution 
to characterise our uncertainty in the nature and direction of heterogeneity around coefficients. 
Triangular and lognormal distributions were tested and did not change the sign or significance of the 
main effects. General population samples were analysed with survey weighting such that age and sex 
characteristics matched those of the general population. FSW RDS data were weighted using age 
characteristics using RDSAT software.52 All attribute levels were effects coded1, except for HIV 
protection which was estimated linearly.53 
Results 
Sample characteristics and generalisability 
In the household survey, of 2271 persons identified door-to-door, 650 were eligible (29%). Of those, 
30 (5%) were not found after five attempts and 11 (2%) refused to be interviewed, leading to 609 
(94%) completed interviews. In total 661 interviewees met the DCE eligibility criteria across the four 
populations. Notably, 126 (62%) of adolescent girls reported not being sexually active whilst self-
reported HIV prevalence was broadly comparable across and within populations to that of other 
representative surveys.3, 4 The inclusion criteria for adolescent girls did not require sexual activity 
because adolescent girls face substantial and immediate risk of HIV at sexual debut, whilst HIV 
                                                          
1 Effects coding is similar to dummy coding in that it allows for non-linear effects in attribute levels, but does 
not perfectly confound the base attribute level with the grand mean of the utility function. Coefficients are 
therefore interpreted as divergence from the mean for that attribute 
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prevention programmes do not target based on reported sexual activity. The preferences of non-
sexually active adolescent are important for ensuring that attractive products are made available at 
the earliest possible exposure to HIV risk. In addition, if sexual activity was an explicit inclusion criteria 
for adolescents, confidentiality could have been breached if other members of the household knew 
that an interview did, or did not, take place.  
<Table 2 here> 
Table 2 displays the descriptive statistics for eligible respondents in each population. Comparability is 
limited across groups due to varying inclusion criteria for adolescent girls and FSWs, the latter also 
sampled through RDS. The mean age across adult groups was similar and whilst a large number of 
respondents in each group reported being in a relationship, many fewer reported cohabiting with a 
sexual partner. Reported lifetime sexual partners among adult males (13.06) were higher than among 
adult females (4.55). Reported condom use at last sex with a regular partner was significantly lower 
among adult females (43%) than any other group, though this figure is comparable with that of 34% 
from a nationally representative survey.3, 4  
The DCE was well understood by participants; just 2% of respondents reported finding the DCE quite 
difficult or very difficult, whilst 81% of respondents chose the same alternative twice in the repeated 
choice task. 61% of respondents chose the product (or one of the products when values were 
duplicated) with the highest HIV protection in every choice set. 
Analysis of preference data 
<Table 3 here> 
Table 3 shows MMNL results and reports the coefficients of each attribute level parameter. Results 
from the MNL model are given in supplementary table 2. Where coefficients are significantly greater 
than zero, an attribute can be interpreted as having a relatively positive impact on participant utility. 
The magnitude of coefficients can be directly compared within each model. The significance of 
coefficients (i.e. what is important to people’s choices) can be compared across populations, but due 
to possible differences in the scale of choice data across groups, coefficients cannot be directly 
compared across populations. In both specifications and across all groups HIV protection was the 
strongest determinant of choice, whilst protection against pregnancy and other STIs was also 
significantly attractive. The absence of side-effects was important to adult men but not to any female 
groups, although FSWs found nausea significantly worse than other side-effects. There was no clear 
pattern of demand around frequency of use across groups. 
There are some differences between the product coefficients in the MNL and MMNL models, 
indicating that tastes vary within populations – this is also highlighted by the positive distribution 
parameters. In both specifications adult women and FSWs significantly dislike oral PrEP and favour 
injectable products, with FSWs additionally disliking microbicide gels. Among adolescent girls, the 
MNL indicates a significant dislike for the vaginal ring which is insignificant in the MMNL model, whilst 
the MMNL model shows the same pattern of statistically significant preferences for oral PrEP and 
injectable products as other female groups.  
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Preference Heterogeneity 
Latent class specification 
<Table 4 here> 
Latent class models are presented for female and male respondents in panels A and B of Table 4 
respectively, and were computed without survey weighting. HIV knowledge (as assessed through the 
a tool presented in Supplementary Material 1) is a key driver of demand for HIV protection as Class 1 
members (34% of the female sample) show strong preferences for STI and pregnancy protection but 
do not value HIV protection in a new product. Class membership is additionally predicted by being of 
younger age, a FSW, or an adolescent, indicating that there is significant variation in preferences 
among female groups. A HIV preventive MPT would offer substantial benefit to this group of women, 
as contraceptive or STI preventative products could be bundled with HIV protection, offering 
additional protection. 
In contrast, members of class 2 (19% of the sample) display very strong preferences for HIV protection, 
valuing it more than twice as highly as other classes. Class 2 members also value pregnancy protection, 
but do not find STI protection appealing. Class 2 appears to be a high-risk group as, relative to class 3, 
members are more likely to have used alcohol the last time they had sex, and have lower HIV 
knowledge. Finally, class 2 members are more likely to be FSW or adolescent girls than class 3 
members, and indicate a dislike for coitally-specific products. Class 3 members (48% of the sample) 
strongly value protection from HIV, pregnancy and STIs, and indicate a dislike for the vaginal ring 
product. This group is likely to comprise of adult women in the general population. 
Among adult males, membership of either class (42%) is not significantly predicted by the 
characteristics we define, indicating that drivers of preference heterogeneity differ between men and 
women and that male preferences are not shaped by structural risks in the same manner as female 
preferences. However there is still evidence of heterogeneity in preferences among adult men. The 
most notable variation between the two groups is the non-significance of the pregnancy prevention 
parameter among class 2 men indicating that, in order to make HIV prevention products attractive to 
these men, potential HIV and STI prevention properties should be emphasised. Men in class 1 strongly 
prefer oral PrEP, whilst the strongly significant opt-out parameters in both groups show an inclination 
to continue current practice suggesting that the expected reporting bias towards switching to new 
products may not be as strong as hypothesised.  
Marginal effects 
DCEs estimate the relative strength of preferences, and therefore we cannot simply compare the 
magnitude of coefficients across groups. However, the ratios of coefficients are comparable across 
populations and show the variation in trade-offs across groups. The marginal effects of factors relative 
to the common denominator of HIV protection are provided in supplementary table 3, computed from 
the coefficients in table 3. Adult men are only willing to forgo 3% HIV protection for a contraceptive 
product, but adult women are willing to forgo 11%. Results suggest that all female groups value the 
male condom substantially more than men, and that preferences for STI protection is broadly 
comparable to pregnancy protection across female groups. Men value the absence of side-effects 
much more than women and FSWs value STI protection almost three times greater than any other 
group. 
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Discussion 
This study assessed preferences for new HIV prevention products among adult men and women, 
adolescent girls, and female sex workers. Consistent with prior expectations HIV protection was the 
most important attribute to respondents, particularly those with high levels of HIV knowledge, 
however, results suggest that demand would increase for all groups if multipurpose protection was 
incorporated. There was relatively little variation in preferences for oral PrEP, microbicide gel, the 
SILCS diaphragm and the vaginal ring when compared to strong preferences for a long-lasting 
injectable ARV. This could be influenced by the strong awareness and use of injectable contraceptives 
in South Africa.54 
This study also provides evidence to explain data from clinical trials of new HIV prevention products. 
Neither adult women nor adolescent girls found the vaginal ring appealing, whilst an injectable 
product was favoured by all groups. In the context of trial data suggesting that younger women were 
not able to adhere to vaginal ring use to the same extent as older women8, 9, these results suggest that 
younger women in particular do not favour a vaginal ring prevention system. Incorporating 
multipurpose properties to a vaginal ring could mitigate some of the intrinsic dislike of this product, 
however, these data suggest that a vaginal ring product will not be an attractive offering for younger 
populations. 
Importantly this study suggests that, in order to fully catch the attention of AGYW, products must not 
be single-purpose but provided to offer multipurpose prevention against HIV, pregnancy, and other 
STIs. AGYW have been identified as key populations in HIV prevention, and it is critical that new 
biomedical products are made to be attractive and easy for these women to use.3 Although MPT 
products are generally at the concept stage of development, bundling PrEP with other sexual and 
reproductive health services may make it more attractive than vertical programmes until such time as 
an MPT is licensed. 
Although there are some similarities across groups, the divergence in preferences shown here can 
provide useful information for programming. Adolescent and adult females are unlikely to be put off 
by minor side-effects and demonstrate comparable, statistically significant preferences for STI and 
pregnancy protection. Adult women, however, are much more likely to find the male condom 
appealing relative to new products, indicating that demand for ARV-based prevention may be less 
among older, lower-risk women who may prefer on-demand methods. Products rolled out into higher-
risk groups (such as AGYW) are more likely to be cost-effective – as long as they can be used 
consistently and effectively.55 Findings from the latent class analysis show notable segments in the 
market for PrEP, with some women very concerned about HIV and STI protection, and others who are 
not at all. In addition, female sex workers demonstrate a much stronger preference for STI protection 
than any other group, perhaps because STI acquisition is more likely to immediately affect earnings 
than HIV or pregnancy.56  
Finally, these results suggest that a one size-fits all HIV prevention package will not be an effective or 
efficient use of resources. This is consistent with recent trajectories of contraceptive and HIV research  
where it has been recognised that a range of options can optimise uptake and adherence.57 Because 
groups have different preferences and needs, further highlighted by these results, there is a strong 
case for greater tailoring of prevention services, for at risk young women in particular. 
12 
 
This study has some limitations. Firstly, DCEs are hypothetical tools and may not correlate perfectly 
with real-world choices. However, recent evidence shows that DCEs conducted in health fields predict 
real world choices with a relatively high sensitivity, suggesting a reasonable degree of external 
validity.58 Overall, the random sample of the general population survey design and the similarity of 
sample descriptive statistics with other representative surveys mean findings may have relevance for 
other South African settings. Self-reported rates of condom use among males and adolescent girls 
were higher than other representative surveys and may indicate acceptability biases in reporting, or 
that condoms were more readily available to this group than others. This study did not include a price 
attribute, and therefore does not enable the calculation of willingness to pay estimates for different 
products. However, given the South African context where prevention products will likely be free-of-
charge to potential users in the public sector, including a price element would have made the choice 
task unrealistic. Product profiles in the DCE do not perfectly match with candidate products in 
development, for example injectable trials are based on administration every eight weeks rather than  
every four or twelve explored in this DCE, whilst rare but serious side-effects were not included in the 
choice tasks. In addition, injectable products may be more likely to initiate drug resistance as they 
have been shown to remain in the body at a low level59, and this is not included here. Finally, there is 
a lively literature discussing the reliability of RDS to generate generalisable samples suggesting that, 
at worst, RDS is a superior form of convenience sampling for hard-to-reach populations and, at best, 
produces bias-free and generalisable samples.32, 60  
Further research is needed to estimate the impact and cost-effectiveness of potential single- and 
multi-purpose HIV prevention products. If models do not incorporate the variation in product 
preferences that we observe here and instead assume an average uptake across groups, they may give 
misleading results. Because models are used to generate impact predictions for investment cases in 
low- and middle-income countries (e.g. in South Africa61), inaccurate predictions could result in 
reduced efficiency in the allocation of resources, and large opportunity costs in terms of benefits 
forgone. This paper shows that particular attention should be paid to the perspectives of different 
groups of end-users. 
Conclusion 
This study involved a discrete choice experiment among four groups in Ekurhuleni Municipality in 
South Africa. In general, respondents indicated a strong desire for products that are highly effective 
in preventing HIV infection. However, there was strong demand across all groups for multipurpose 
prevention products to protect against other STIs and pregnancy. Further analysis shows substantive 
heterogeneity across and within groups, suggesting that a variety of prevention methodologies are 
required to meet the demands of different groups. These results strengthen the call for effective and 
attractive multipurpose prevention technologies to be deployed as part of a comprehensive 
combination prevention strategy. 
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